MAPK3 and glioblastoma: The phosphorylation levels of EGFR, AKT and ERK1/2 in the erlotinib-treated, TAZ-overexpressing GBM cells were significantly decreased compared to those in the cells without erlotinib treatment (Figure 6A, 6B, 6D, and 6E).